Eli Lilly and Co / LLY

Equity | Generated Sep 18, 2026 11:32 PM EDT

Current price	Daily move	Bid / Ask	Previous close
$1,154.00	**+1.56 +0.14%**	**-/-**	**$1,152.44**

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Sep 18, 2026 11:32 PM EDT**

JW Intelligence Report

Complete | 3 of 3 sections | Sep 18, 2026 7:51 PM EDT

JW Rank	Rank label	Confidence	IV percentile
64.2 / 100	**Balanced**	**high**	**16 / 100**

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,140.00	**$1,195.00**	**$1,105.00**	**71 / 100**

Options stance	**bullish**
Tail-risk safety	**56 / 100**
JW Rank data coverage / as of	**100.0% | Sep 18, 2026 7:51 PM EDT**

Key insight

LLY Option Market Implies Continued Growth and Upside Potential

Market read

The US options market for LLY suggests a cautiously optimistic outlook, driven by strong fundamentals, recent positive news, and analyst upgrades. While short-term technicals are mixed, the underlying trend remains bullish with support at $1,063 and resistance at $1,178. Implied volatility is elevated but not extreme, reflecting investor anticipation for upcoming earnings and data readouts.

Strategy context

The market is pricing in potential upside from upcoming earnings, obesity drug launches, and pipeline progress. Investors are also considering risks related to valuation, competition, and regulatory policy.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Mixed**
AI analysis updated	**Sep 18, 2026 2:06 PM EDT**

Short-term scenario

Cautious/speculative buy on dip or hold for confirmation of bounce given mixed short-term technicals (below 50-day MA, negative MACD) versus strong fundamentals and upgrades. High uncertainty from pending EASD data, potential policy news, and consolidation. Not a high-conviction 1-3 week trade; position small if entering.

Three-month outlook

Constructive/positive bias toward $1,280-1,350 range if obesity franchise (injectables + oral Foundayo) and pipeline (retatrutide, oncology, mental health) continue delivering and guidance is met/exceeded. Raised 2026 outlook and analyst upgrades support. Key uncertainties/risks: premium valuation, GLP-1 competition, manufacturing/supply, and regulatory/pricing policy (e.g., MFN discussions). Execution on new launches and data readouts will be pivotal; volatility likely.

Market sentiment

Cautiously bullish overall. Recent posts highlight Berenberg upgrade to Buy/$1,400 and Guggenheim Buy/$1,284, plus optimism on EASD data, Foundayo launch, obesity drugs expanding into standard of care for comorbidities, and acquisitions. Some technical notes of holding support/bull flag or oversold bounce potential. Counterpoints include lingering valuation concerns, short-term technical weakness, and policy risks. Analyst/retail lean positive on growth story amid upgrades.

Supporting evidence

Analyst upgrades to Buy with price targets above current levels. | Positive news flow regarding FDA approvals and pipeline advancements. | Strong revenue growth and raised guidance for 2026. | Bullish technical indicators like the uptrend in longer-term moving averages.

Risk watch

Potential headwinds from discussed Medicaid pricing negotiations.

Enhanced price structure

45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor

JW RANK FACTOR PROFILE	COVERAGE	0 – 50 – 100
Liquidity	100.0%	92.4
Strategy Fit	100.0%	70.6
Technical Trend	100.0%	56.5
Market Tail Risk	100.0%	56.3
Fundamental Quality	100.0%	84.2
Volatility Pressure	100.0%	47.3

Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
bullish_recovery	**Below MVWAP**	**Above 200D trend**	**medium**

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**BULLISH RECOVERY | neutral | MACD accelerating**
Trend signal	**BULLISH RECOVERY**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**54.06 / 47.24 / 48.10**
RSI velocity	**1.75**
MACD line / signal / histogram	**-13.70 / - / -13.50**
MACD acceleration	**1.36**
Stochastic K / D	**45.64 / 34.08**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Below institutional MVWAP | Distribution bias**
Institutional flow	**-6.55**
20-day MVWAP	**$1,169.97**
Price vs 20-day MVWAP	**-1.36%**
Daily reference VWAP	**$1,150.27**
Price vs daily reference	**+0.32%**
Volume	**1.22M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Negative macro velocity**
Macro velocity	**-5.12**
20-day / 200-day SMA	**$1,163.31 / $1,066.35**
Bollinger range	**$1,082.68 - $1,243.95**
Bollinger position	**0.436**

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
17 / 100	**13 / 100**	**87.89**	**145.70**

Market regime	**Calm**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**flat**
Term slope	**+1.18 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 18, 2026 2:52 PM EDT**
Options data quality	**Coverage 88.9%**

Option term structure

ATM implied-volatility curve by days to expiration

ATM IV CURVE



Upward-sloping ATM volatility term structure

EXPIRATION	DTE	ATM IV	STATE
2026-09-25	7	29.9%	-
2026-10-02	14	31.5%	-
2026-10-09	21	31.1%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bear Call Spread reference

Short $1,190.00 | Long $1,195.00 | Width $5.00 | Net credit $0.98



Max profit $98.00 | Max loss -$402.00 | Break-even $1,190.98 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**NOT MEASURED**
VIX	**14.97**
VVIX	**87.89**
SKEW index	**145.70**
Observation confidence	**high**
Option quote quality	**reliable**
Contracts observed	**127**
Contracts with quotes	**127**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The US options market for LLY suggests a cautiously optimistic outlook, driven by strong fundamentals, recent positive news, and analyst upgrades. While short-term technicals are mixed, the underlying trend remains bullish with support at $1,063 and resistance at $1,178. Implied volatility is elevated but not extreme, reflecting investor anticipation for upcoming earnings and data readouts.

Options context

LLY Option Market Implies Continued Growth and Upside Potential

Wheel context

The market is pricing in potential upside from upcoming earnings, obesity drug launches, and pipeline progress. Investors are also considering risks related to valuation, competition, and regulatory policy.

Observed evidence

Analyst upgrades to Buy with price targets above current levels. | Positive news flow regarding FDA approvals and pipeline advancements. | Strong revenue growth and raised guidance for 2026. | Bullish technical indicators like the uptrend in longer-term moving averages.

Principal risks to monitor

Potential headwinds from discussed Medicaid pricing negotiations.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization **$1.08T**	P/E (TTM) **40.41**
ROE **92.6%**	Revenue growth **31.7%**
EPS growth **49.3%**	Operating margin **42.2%**
Net profit margin **33.5%**	Gross margin **-**
Free cash flow CAGR **5.9%**	Debt / equity **1.60**
Dividend yield **0.8%**	Beta **0.43**
52-week range **$712.05 - $1,292.65**	

Company or fund profile

Issuer identity and classification

Name **Eli Lilly and Co**	Market **NYSE**
Industry **Pharmaceuticals**	Country **US**
Currency **USD**	IPO date **1970-07-09**
Shares outstanding **941.74M**	52-week return **48.8%**
Book value per share **$35.98**	Revenue per share **$89.14**

Website	**lilly.com**

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Sep 18, 2026 10:19 AM EDT

Covered Call | 2026-09-25

At signal $1,149.70 | Current $1,154.00

SHORT **Option $1,150.00 B $18.50 / A $21.00**

High turnover | Conservative | CR $19.75

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$29.50**
ATR as % of price	**2.6%**
Volatility environment	**medium**
Current IV	**30.9%**
IV rank	**18 / 100**
IV percentile	**16 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Sep 18, 2026 3:51 PM EDT**

Technical health and risk radar

Derived indicator health and event context

Overall health	**82 / 100**
Trend health	**78 / 100**
Momentum health	**86 / 100**
Volatility health	**72 / 100**
Structure health	**94 / 100**
Earnings risk / date	**low | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,163.31 / $1,177.36 / $1,066.35**
EMA (9 / 21)	**$1,144.46 / $1,157.53**
Bollinger upper / middle / lower	**$1,243.95 / $1,163.31 / $1,082.68**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.436**
True high / low	**$1,157.60 / $1,140.27**
5-day true high / low	**$1,161.00 / $1,115.70**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	-5.121	**-**
SMA50	-1.501	**-**
MVWAP20	-6.546	**-**
MACD	1.362	**-**
RSI	1.752	**-**
Volume	147988.000	**-**
ATR	-0.851	**-**
T1	-	**-15.35 / 1175.93 / 1159.75 / 1137.82**
T2	-	**-17.19 / 1186.85 / 1151.23 / 1132.63**
T3	-	**-17.79 / 1189.61 / 1161.00 / 1131.59**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,154.70**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 18, 2026 2:52 PM EDT**
Options data coverage	**88.9%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FLAT**
Front expiration / DTE	**2026-09-25 | 7 DTE**
Front at-the-money IV	**29.9%**
25-delta skew	**0.72**
Put / Call 25-delta	**$1,125.00 Delta -0.253 / $1,190.00 Delta 0.248**
Median option bid/ask spread	**20.7%**
Bid/ask spread	**-**
Contracts observed / quoted	**127 / 127**

Price context

Last Price: 1,154.70 | Bid: 1,154.54 | Ask: 1,155.40 | Previous Close: 1,152.44 | Change: 2.26 | Daily change: 0.20% | Update Time: 2026-09-18T14:52:32.531936-04:00 | Latest History Date: 2026-09-18 | Latest History Price: 1,154.70

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-25 | Latest Date: 2026-09-18 | Latest Price: 1,154.70 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 30.68% | Iv Rank: 16.61 | Iv Percentile: 13.15 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-08-13

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Sep 18, 2026 11:32 PM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**